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ABSTRACT 
Tumor Necrosis Factor Alpha (TNF-a) is a vital pro-inflammatory cytokine 
produced in response to the activation ofthe innate immune response via the Toll-like 
receptor signal transduction pathway. This thesis explores the release and inhibition of 
TNF-a from RAW 264.7 mouse macrophages and human U937 cells that have been 
exposed to a potent activator of innate immunity. Using lipopolysaccharide (LPS), a 
Gram negative bacterial endotoxin, in the presence or absence of proinflammatory 
cytokine interferon 'Y (IFN-y) as activators ofthe TLR-4 pathway, a robust release ofTNF­ 
a was observed. Co-incubation of stimulated macrophages with the tyrosine 
phosphatase inhibitor, sodium vanadate, resulted in a time and concentration 
dependent inhibition of stimulated TNF-a release. These results demonstrate for the 
first time that soluble TNF-a release can be inhibited by a small molecule tyrosine 
phosphatase inhibitor, and indicates that protein tyrosine phosphorylation is critical to 
macrophage TNF-a release. Since the inappropriate expression of TNF-a occurs in the 
pathogenesis of many chronic inflammatory disorders, these results provide a 
potentially novel mechanism for regulating macrophage TNF-a release. 
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INTRODUCTION 
In our everyday lives there exists a constant exposure to harmful pathogens that 
challenge our innate immune system and prime its response to suppress potential 
pathogens. One critical sentinel of innate immunity is the monocyte/macrophage. 
When monocytes are acutely exposed to pathogens such as the Gram-negative bacterial 
endotoxin, lipopolysaccharide (LPS), they respond by producing pro-inflammatory 
cytokines which serve to neutralize the immune challenge. On the macrophage's cell 
surface, Toll-like receptors (TLR) initiate the cellular response. Upon LPS binding to 
CD14 and stimulation of the TLR receptor, intracellular adaptor proteins are recruited, 
resulting in the activation of protein kinase cascades, such as the lkappaB kinase (IKK) 
and mitogen-activated kinase (MAPK) pathways (Guha and Mackman, 2001). 
The initiation and propagation of the cellular response activated by LPS relies on 
a tightly orchestrated series of enzymatic reactions. The structural components of LPS, 
especially its lipid A portion is vital for recognition and thus activation of the 
inflammatory pathway. Once LPS is introduced into a system it binds a serum protein, 
LPS-binding protein (LBP), which facilitates its delivery to the cell surface receptor CD14. 
CD14 is bound to the cell surface via glycoplipid linkages but requires additional proteins 
to carry out transmembrane signaling. The newly formed CD-14/LBP/LPS complex 
activates the receptor, TLR-4 and its accessory protein, MD-2. TLR-4 and MD-2 form a 
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complex that initiates an intracellular signaling cascade. At the extracellular surface, 
MD-2 associates with TLR-4 through its leucine-rich repeats (LRR) and binds LPS directly. 
Upon ligand stimulation, TLR-4 is oligomerized and an adaptor protein, myeloid 
differentiation factor 88 (MyD88), associates with TLR-4 via the intracellular Toll/lL-1 
receptor (TIR) domain. MyD88 possesses two domains: a TIR domain at the (-terminal 
end and a death domain at the N-terminal end. MyD88 also associates with TIR domain­ 
containing protein (TIRAP). Because TIRAP contains a phosphatidylinositol 4,5- 
bisphosphate (PIP2) binding domain, it facilitates MyD88 delivery of the activated TLR-4 
to the membrane (Tanimura et al, 2008). 
MyD88 then recruits IL-1 receptor-associated kinase 1 (IRAK-1) to TLRs by 
interaction of death domains of the two molecules. This allows the subsequent 
association of IRAK-4 which serves to phosphorylate and thus activate IRAK-1. Once 
activated IRAK-1 partners with TNF receptor associated factor 6 (TRAF-6). The 
oligimerization of TRAF-6 activates its ligase activity, leading to polyubiquitination of 
target proteins such as TRAF-6 itself (Chen et al, 2008). This ubiquinated TRAF-6/IRAK-1 
complex will then activate TAK-1 binding protein (TAB-1) and TGF-P-activated kinase 1 
(TAK-1) (Takeda and Akira, 2004). TAK-1 and TAB-1 are responsible for triggering IKB 
kinase (IKK) and mitogen-activated protein kinase (MAPK) pathways. 
These pathways are further broken down into their components. IKKa, IKKP and 
IKKy of the IKK pathway associate with one another to form a complex that is 
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responsible for phosphorylating IKB proteins. IKB proteins serve as inhibitors of the K 
light chain gene enhancer in B cells(Lu et al, 2008), which contain a number of copies of 
ankyrin repeat sequences which actually mask the nuclear localization signal (NLS) of 
NF-KB proteins (Jacobs and Harrison, 1998). The masking ofthe NLS results in 
maintenance of NF-KB proteins in its inactive form and thus the form found sequestered 
in the cytoplasm. Phosphorylation of this inhibitory protein, IKB, leads to its 
ubiquitination which then leads to its degradation by proteosomes (Jacobs and Harrison, 
1998). With IKB degraded, the transcription factor, NF-KB, is no longer restricted and 
moves into the nucleus where it activates the transcription of pro-inflammatory 
cytokines and many other immune associated genes. LPS exposure also triggers the 
MAPK pathway which is activated along with the IKK pathway. The MAPK pathway also 
ultimately leads to the activation of the AP-1 transcription factor which is fundamental 
to the expression of pro-inflammatory cytokines such as TNF-a, IL-1� and IL-6 (Trahn-Thi, 
1995). 
While this complex TLR-4 signal pathway is essential in amplifying the signal 
initiated by LPS, numerous levels of regulation exist. For example, there are protein 
inhibitors at the cell surface such as radioprotective 105 (RP105) and MD-2 homolog, 
MD-1. RP105 and MD-1 form a complex that interacts with the TLR-4/MD-2 complex to 
directly inhibit its association with LPS (Lu et al, 2008). Also, once activation has already 
begun there are a number of additional negative regulators that serve to regulate the 
pathway such as triad domain-containing protein 3 variant A (TRIAD3A) and suppressor 
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of cytokine signaling-1 (SOCl-1). TRIAD3A and SOCl-1 promote the degradation of many 
of the key pathway components such as TLR-4 and TIRAP (Lu et al, 2008). Acting even 
further downstream are the negative regulators IL-1 receptor-associated kinase M 
(IRAK-M)and A20. Previous studies suggest that despite its name IRAK-M lacks kinase 
activity and works in inhibitory manner by preventing the dissociation of MyD88 from 
IRAKs (Wesche et al, 1999). A20 is an enzyme the de-ubiquinates thereby removing 
ubiquitin moieties from TRAF-6 (Lu et al, 2008). As noted earlier, the non-ubiquinated 
form ofTRAF-6 will not be able to complex with IRAK-1 to recruit TAB-1 and TAK-1 thus 
terminating the downstream signaling events (Figure 1). 
While protein kinases are known activators of macrophages TNF-a release, the 
role of protein phosphatases, which regulate kinase function, remains unclear. 
Analogous to protein kinases, protein phosphatases fall into three general categories: 
serine/threonine phosphatases, tyrosine phosphatases and dual specificity 
threonine/tyrosine phosphatases (Barford, 2002) Protein phosphatases are generally 
categorized by functional inhibitors, for example while serine/threonine phosphatases 
are differentially inhibited by natural products, such as okadaic acid, tyrosine 
phosphatases can be inhibited by a range of products such as small molecules and 
synthetic chemical compounds (reviewed in Heneberg, 2009). Protein tyrosine 
phosphatase (PTP) inhibition leads to an up-regulation of kinase activity (Hooft van 
Huisduijnen et al, 2002). In the current study, we examine the effects of a broad 
spectrum tyrosine phosphatase inhibitor, sodium vanadate, on endotoxin stimulated 
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macrophage responses. We find that sodium vanadate inhibits macrophage TNF-a 
release in a concentration and time-dependent manner. Our results provide the first 
experimental evidence that tyrosine phosphatases are critically involved in TNF-a 
release. 
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Figure 1. Toll-Like Receptor (TLR) Pothwoy. The modified image demonstrates the LPS 
activated TLR-4 pathway, illustrating adaptor proteins, kinases, transcription factors and 
cytokines produced during an inflammatory response. Modified from lnvitrogen Corporation. 
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MATERIALS AND METHODS 
Cell Culture 
The human leukemic monocyte lymphoma cell line (U937) was obtained from 
American Type Culture Collection (ATCC; Manassas, VA) and maintained with Roswell 
Park Memorial Institute (RPMI) growth medium (lnvitrogen; Carlsbad, CA) plus 10% fetal 
bovine serum and 1% penicillin/streptomycin. Cells were grown at 37"C in a humidified 
atmosphere in the presence of 5% C02• Cells were maintained in T-75 cm
2flasks and 24- 
well cell culture dishes (Corning; Corning, NY). The mouse macrophage cell line, RAW 
264.7, was obtained from the ATCC and was propagated in culture as described (Dos 
Santos et al, 2007). RAW 264.7 cells were maintained in 100 mm2 culture dishes in 
RPMI medium with 5% fetal calf serum in a humidified atmosphere with 5% C02• All 
solutions and plastic-ware were cell culture grade, endotoxin free. Cells were routinely 
passaged at 70% confluence and split 1:10 (dish:dish ratio). Cells used in experiments 
are allowed to recover for 48 hours prior to experimentation. 
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Enzyme Linked lmmunosorbent Assay 
Soluble TNF-a levels were quantified using a commercially available enzyme 
linked immunosorbent assay (ELISA) kit (Biolegend; San Diego, CA). U937 and RAW 
264. 7 cells were cultured separately in 24-well cell culture plates (Corning; Corning, NY) 
at a density of 40,000 cells/ml for 48 hours or until 90-100% confluency was achieved. 
After this incubation period, cell were washed with Dulbecco's Phosphate Buffered 
Saline (DPBS) (Sigma-Aldrich; St. Louis, MO ) and treated with Opti-MEM, a serum-free 
cell culture media {lnvitrogen; Carlsbad, CA) . 
After 12-18 hours of incubation with Opti-MEM, the media was removed and the 
cells were treated with lipopolysaccharide (LPS), interferon gamma (IFN- y) and sodium 
vanadate. One control and six experimental groups were used (Table 1). The cells were 
treated with 10 µg/ml LPS {lnvitrogen; Carlsbad, CA) in the presence or absence of 
lOng/ml IFN-y (Sigma-Aldrich; St. Louis, MO). TNF-a inhibition experiments were 
carried out in the presence of 100 µM sodium vanadate (Sigma-Aldrich; St. Louis, MO ). 
The treated cells were incubated at 37"C and the supernatants were collected after 2 
hours. For time courses the same steps were taken up until sample collection. Instead, 
samples were collected at O minutes, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 
hours, 4 hours and 6 hours. Each sample was frozen at -80°C upon collection before 
assay. 
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Cell supernatant samples were then thawed on ice to avoid TNF-a degradation. 
Once the samples were thawed, there were analyzed using ELISA MAX™ Deluxe Sets to 
quantify levels of soluble TNF-a. One day prior to running the ELISA, depending on the 
cell type being analyzed, human or mouse TNF-a capture antibody is added to the NUNC 
Maxisorp 96 Micro Well Plates and left to incubate at 4 "C overnight. The plate was then 
washed 4 times with 300 µL wash buffer and blotted dry each time. Because the 
capture antibody does not cover the surface of the high-affinity binding plate in its 
entirety, there are spaces left empty where protein may attach and in turn, cause a false 
reading. In order to block non-specific binding to these empty spaces, 200 µL of assay 
diluent was added to each well and allowed to incubate for one hour at room 
temperature. The assay diluent contains proteins that will attach to the surface of the 
plate thereby minimizing non-specific interaction of other proteins such as the antigen 
to the surface of the plate. The blocking step was then followed by four washings. 
Next 100 µL of each sample was loaded into each well. A TNF-a standard curve 
was generated for each ELISA plate and all treatments were performed in triplicate. The 
standard curve was made up of the following TNF-a concentrations: 500 pg/ml, 250 
pg/ml, 125 pg/ml, 62.5 pg/ml, 31.3 pg/ml, 15.6 pg/ml, 7.8 pg/ml and O pg/ml. All 
sample dilutions were carried out with assay diluents. Loading of the samples into the 
wells was followed by a 2 hour incubation period at room temperature with gentle 
shaking. After, the plate was washed once again four times with wash buffer, and then 
treated with 100 µL ofTNF-a detection antibody. This was followed by a 1 hour 
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incubation period at room temperature with shaking and subsequent washes. Next, 100 
µL of Avidin-HRP (Horse Radish Peroxidase) was added and let to incubate for 30 
minutes at room temperature with shaking. This was followed by four washes but in an 
effort to minimize background the last wash was prolonged allowing the wash buffer to 
soak the wells. 
Next, 100 µL of a fresh solution oftetramethylbenzidine (TMB) substrate 
solution was added to each well and left to incubate in the dark for 15 minutes at room 
temperature. TMB must be handled in the dark because it is a photosensitive 
chromogenic substrate and exposure to light may nullify results. Finally, 100 µL of stop 
solution (sulfuric acid) was added to each well causing immunoreactive positive wells to 
change color from yellow to blue. Using the 5PECTRAmax250 plate reader (Molecular 
Device; Sunnyvale, CA), TNF-a levels were determined using the cleavage of TMB 
substrate to its oxidized form indicating the concentration ofTNF-a present in each well 
(Abs 450 nm and 570 nm). 
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Treatment Groups 
Basal LPS 
sodium 
IFN- y LPS+ IFN- y 
LPS + sodium LPS+ IFN-y + 
vanadate vanadate sodium vanadate 
Table 1. Treatments used far ELISA. The U937 and RAW 264.7 cells were treated in the above 
manner. Cells were treated with 10 µg/ml LPS, 10 ng/ml IFN- y and 100 µM sodium 
vanadate. Stock solutions were diluted in Opti-MEM. 
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Statistical Analysis 
All results were calculated and presented as the mean ± SEM for each control or 
treatment group. Statistical comparisons between the means of different groups were 
performed by multiple ANOVA with a Neuman-Keuls multiple comparison post- 
test. Statistical comparisons and analysis were performed with GraphPad Prism 4 and 
statistical significance was defined as p<0.05. 
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RESULTS 
Soluble TNF-a Secretion 
TNF-a is a critical pro-inflammatory cytokine. In our studies, U937 and 
RAW264.7 cells were used as a monocyte model system to assess the effects of LPS, IFN­ 
y, and sodium vanadate on soluble TNF-a levels which were stimulate by the Gram 
negative bacterial endotoxin, LPS. LPS activates a robust and sustained TNF-a response 
in our cell models, thereby making these cells a valuable model for studying pro­ 
inflammatory cytokine release (Guha and Mackman, 2000). Untreated U937 cells 
demonstrated basal release ofTNF-a at a level of 105 pg/ml (see Fig 1). Treatment of 
U937 cells with 10 µg/ml LPS increased TNF-a levels to 560 pg/ml translating into an 
increase by 455 ± 40 pg/ml from basal (see Fig 2, **p<0.001 basal versus LPS treated). 
Treatment with lOng/ml IFN-y stimulated the release of TNF-a to 375 pg/ml thus 
increasing by 270 ± 55 pg/ml from basal (see Fig 2, *p<0.01 basal versus IFN-y treated). 
When cells were treated with both LPS and IFN-y together 515 pg/ml TNF-a was 
released increasing by 410 ± 35 pg/ml (see Fig 2, **p<0.001 basal versus LPS + IFN-y 
treated). All three of these experimental groups caused a significant increase in TNF-a 
levels. On the other hand, treatment of U937 cells with sodium vanadate, a broad 
spectrum protein tyrosine phosphatase inhibitor, left TNF-a levels at 108 pg/ml, a value 
very close to that of basal levels. Sodium vanadate suppressed LPS stimulated TNF-a 
from 560 pg/ml to 130 pg/ml when cells were treated with LPS in the presence of 
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sodium vanadate. Similarly, when cells are treated with IFN-y and LPS in the presence of 
sodium vanadate there is a decrease to 185 pg/ml TNF-u from the 375 pg/ml seen with 
cells treated with IFN-y alone (see Fig 2). 
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Figure 2. ELISA reveals levels of soluble TNF-a secretion from U937 cells. U937 cells 
were treated with [10 µg/ml] LPS and [10 ng/ml] IFN-y in the presence or absence of 
[lOOµM] Na3V04. Cell supernatants were collected after 2 hours of incubation and 
soluble TNF-a quantified by ELISA. Data are means +SEM from two independent 
experiments, each performed in triplicate. Data were analyzed by multiple ANOVA 
with Newman-Keuls post hoc test. Using GraphPad Prism statistical significance was 
defined as p<0.05. *p<0.01; **p<0.001. L: LPS; N: Na3V04; g: IFN-y. 
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Quantifying TNF-a release from RAW 264.7 cells in response to lPS +/- IFN-y 
resulted in similar effects as those observed with U937 cells, although we noted a 
substantial difference in the total amount of TNF-a released (see Fig 3). Basal release of 
TNF-a in RAW 264.7 is 442 pg/ml. There is an increase from basal levels to 26,200 
pg/ml TNF-a observed when RAW 264.7 cells are treated with 10 µg/ml lPS (an 
increase by 25,800 ± 3,100 pg/ml from basal) and an increase to 20,600 pg/ml when 
treated with 10 ng/ml IFN-y (an increase by 20,200 ± 1,500 pg/ml from basal). lPS and 
IFN-y together increase TNF-a levels to 31,000 pg/ml TNF-a (an increase by 30,600 ± 
5,000 pg/ml from basal). Cells treated with sodium van ad ate alone have levels of TNF-a 
that remain in the range of basal release; in this case, 528 pg/ml. Once cells are treated 
with sodium vanadate in the presence of lPS and/or IFN-y there is an inhibition of TNF-a 
release. When RAW 264.7 cells are treated with lPS in the presence of sodium 
vanadate TNF-a levels drop to 4,040 pg/ml. Similarly, when cells are treated with lPS 
and IFN-y in the presence of sodium vanadate TNF-a level drop again to 4,020 pg/ml 
(see Fig 3). 
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Figure 3. ELISA reveals levels of soluble TNF-a secretion from RA W264.7 cells. RAW 
264.7 cells were treated with [100 µm] Na3V04, [10 µg/ml] LPS, and [10 ng/ml] IFN-y. 
Cell supernatants were collected after 2 hours of incubation and soluble TNF-a 
quantified by ELISA. Results are the mean from a single experiment performed in 
triplicate. LPS and IFN-y induced TNF- a release was decreased from cells treated 
with Na3V04. L: LPS; N: Na3V04; g: IFN-y. 
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Time Course of TNF-a Secretion 
The TLR signal transduction pathway of the innate immune response elicits a sequential 
pro-inflammatory cytokine response. In U937 cells, basal levels of TNF-a increases 
approximately three-fold over a 6 hour time course ranging from 68 pg/ml at O minutes 
to 210 pg/ml at 360 minutes increasing by 142 ± 16 pg/ml from O minutes (see Fig 4). 
LPS treated U937 cells exhibited an elevated time-dependent increase in TNF-a levels 
increasing from 187 pg/ml at O minutes to 1,580 pg/ml at 360 minutes (see Fig 4; an 
increase by 1390 ± 13 pg/ml from O minutes). IFN--y treated cells also demonstrated in 
increase in TNF-a over time, elevating from 120 pg/ml at O minutes to 1,230 pg/ml at 
360 minutes (see Fig 4; an increase by 1110 ± 25 pg/ml from O minutes). Again, when 
cells were treated with both LPS and IFN--y an increase in TNF-a is seen over time; levels 
increase from 137 pg/ml at O minutes to 1,170 pg/ml (see Fig 4; an increase by 1,000 ± 
33 pg/ml at O minutes). However, cells treated with sodium vanadate showed no 
significant increase in TNF-a throughout the 6 hour period. Cells treated with LPS in the 
presence of sodium vanadate demonstrated a sustained inhibition of TNF-a over time 
ranging from 120 pg/ml at O minutes to 140 pg/ml at 360 minutes. Similarly cells 
treated with both LPS and IFN--y in the presence of sodium vanadate exhibited a 
sustained suppression ofTNF-a release ranging from 120 pg/ml at O minutes and 130 
pg/ml at 360 minutes (see Fig 4). 
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Figure 4. Time course of soluble TNF- a release from U937 cells. The results 
demonstrate a time-dependent increase in LPS and IFN-y TNF- a release. Na3V04 
blocked TNF-a release from these cells. The results shown are the mean+/- SEM for 
three experiments, each performed in triplicate. Data were analyzed by multiple 
ANOVA with a Newman-Keuls post hoc test. Statistical significance was defined as 
*p<0.05. L: LPS; N: NaN04; g: IFN-y. 
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DISCUSSION 
The introduction of foreign pathogens into the body elicits an immediate innate 
immune response and triggers an array of immune cells to synthesize critical 
inflammatory mediators and cytokines. The release of cytokines is fundamental for 
intercellular communication in the immune response. Despite being essential in acute 
inflammation, chronic expression of certain pro-inflammatory cytokines are an 
underlying cause for numerous chronic inflammatory and autoimmune disorders. For 
this reason, understanding the signal transduction and trafficking pathways of cytokines 
such as TNF-u and IFN-y is a vital area of study. 
Activation of the TLR signal transduction pathway initiates an intracellular kinase 
cascade that leads to the activation of transcription factors responsible for producing 
inflammatory cytokines such as TNF- n, Protein kinases are crucial to cytokine release 
and when these enzymes are selectively activated they serve to enable this pathway. 
LPS, a potent Gram negative bacterial endotoxin specifically triggers the TLR-4 pathway 
leading to an activation of a protein kinase cascade that ultimately up-regulates the 
transcription ofTNF-u (Aderem and Ulevitch, 2000) by NF-KB. 
In our studies we demonstrate that LPS and IFN-y stimulate the release of 
soluble TNF-u from both a human monocyte cell line, U937 cell, and a mouse monocyte 
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cell line, RAW 264.7 cells. Monocytic responses to LPS are well documented (Guha and 
Mackman, 2001) and the cellular events that culminate in TNF-a release are well known 
(see Fig 1). Although monocytes also have molecular components that suppress the TLR 
pathway, the availability of a small molecule chemical inhibitor of TLR-induced TNF-a 
release could prove invaluable for experimental studies. Small molecule inhibitors are 
known to exist, but these act predominately through the elevation of intracellular cyclic 
nucleotide levels (Essayan, 1999) or through transcriptional suppression of cytokine 
genes (Gupta et al, 2010). A pathway inhibitor that affects protein phosphatase activity 
has not been explored. 
In this thesis, we demonstrate that the treatment of cells with the pro­ 
inflammatory mediators, LPS and IFN-y in the presence of sodium vanadate inhibits 
stimulated TNF-a levels. Based upon our knowledge of protein tyrosine phosphatase 
inhibitors, such as sodium vanadate, an inhibitor would suppress the effects of 
phosphatases thereby enabling kinases. Because we are studying a kinase enabled 
pathway, the treatment of cells with a phosphatase inhibitor would be thought to lead 
to an up-regulation of the transcriptional products. However, what we observe from 
the ELISA results shown above is that there is an extreme inhibition in soluble TNF-a 
levels when treated with LPS and LPS+IFN-y in the presence of sodium vanadate in 
contrast with LPS or LPS+IFN-y alone. 
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Although the mechanisms for sodium vanadate 's actions have not yet been 
established, numerous potential molecular targets exist. The TLR-4 signaling pathway is 
a tightly regulated cycle employing negative regulators such as IRAK-M, RP105 and A20 
to shut off the pathway once the signal is no longer needed (Kobayashi et al, 2002). One 
speculation is that sodium vanadate may be acting to up-regulate negative regulators 
such as those listed above. Such an up-regulation would lead to an inhibition of the 
players involved in activating NFKb. NFKb is the transcription factor responsible for 
producing TNF-u therefore and inhibition of NFKb will lead to an inhibition of TNF-a 
production. 
TNF-a is an early response cytokine that acts in the recruitment and activation of 
additional immune cells to the site of invasion. Because the ELISA is measuring soluble 
TNF-a, there is a possibility that sodium vanadate may not be interfering with the TLR-4 
signaling pathway but rather acting at a post-transcriptional level. Once transcription is 
achieved in the nucleus, its products, such as TNF-a, must still follow a trafficking 
pathway before they can be secreted out of the cell to carry out cell to cell 
communication. Newly transcribed TNF-a move from the nucleus to the Golgi complex 
and from golgi complex to the recycling endosomes where it finally moves out towards 
the phagocytic cup (Figure 5). Once the TNF-a is at the phagocytic cup the ectodomain 
is cleaved by TNF-u converting enzyme (TACE) resulting in a now soluble cytokine that is 
released by the cell (Stow et al, 2009). If sodium vanadate acts as a TACE inhibitor, 
soluble TNF-a will not be formed and will not be secreted by the cell. If sodium 
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vanadate is indeed a TACE inhibitor it may serve as another explanation for the 
decreased levels of TNF-a shown by the above ELISA quantifications. 
The simplistic route ofTNF-a movement described above involves many 
different proteins such as adaptors, coat proteins, lipids, small GTPases and golgins to 
succeed in efficient trafficking of cytokines. One of the key proteins involved are 
members of the soluble N-ethylmaleimide-sensitive factor attachment protein receptors 
{SNARE) family of membrane fusion proteins. In general, Q-SNAREs complex with R­ 
SNAREs on opposing membranes to allow for fusion of vesicles carrying cytokines such 
as TNF-a. In immune cells the specific components of the abovementioned SNAREs 
responsible for forming the complexes have been identified as syntaxin4 and SNAP23 
from the Q-SNARE family and VAMPS, VAMP7 and VAMP2 from the R-SNARE family 
{Stow et al, 2009). These SNARE proteins are involved in every step of the way from the 
Golgi to the recycling endosome and from the endosome to the cell surface. For this 
reason the levels and concentrations of SNARE proteins have a direct effect on the 
volume and efficiency of cytokine trafficking. Previous studies have shown that siRNA 
knockdown of VAMP3, an R-SNARE protein involved in TNF-a trafficking, led to a 
reduced secretion of cytokines (Manderson et al, 2007). Therefore, sodium vanadate 
interference with the formation of SNARE complexes can serve as an explanation for 
decreased levels of soluble TNF-a. 
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Whatever the molecular target may be, because the presence of sodium 
vanadate has a sustained inhibitory effect on soluble TNF-a that remains unchanged 
over time, it may serve as a treatment for chronic inflammatory and autoimmune 
disorders. Current treatments include protein biologics that use monoclonal antibodies 
specific for TNF-a to remove already secreted TNF-a. However, the treatment of cells 
with sodium vanadate proposes a way to treat these conditions by preventing elevated 
levels of TNF-a before it is even released from the cell. 
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Figure 5. TNF-a trafficking and secretion in macrophages. Proposed model for TNF-a 
release. Once TNF-a leaves the endoplasmic reticulum, it is transported in the Golgi 
complex. From the Golgi, TNF-a is packaged into vesicles to move the cytokine into the 
recycling endosome and out to the surface of the cell, with the dominant release of TN F­ 
a occurring at the phagosome. Taken from Stow et al. Cytokine secretion in 
macrophages and other cells: pathways and mediators. lmmunobiology 214: 601- 
612 (2009). 
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CONCLUSION 
In this study, we reveal the stimulatory effects of LPS and IFN-y on soluble TNF-u 
levels in mouse and human monocyte cell lines, U937 and RAW 264.7. We have 
demonstrated that the presence of sodium vanadate in combination with the 
aforementioned stimulants is responsible for an inhibitory effect on soluble TNF- u 
levels. Although LPS and IFN-y are causing a time dependent increase of TNF- u, once 
cells are treated with LPS and IFN-y in the presence of sodium vanadatethere is a 
sustained inhibition ofTNF- u. The use of two different cell lines has allowed us to make 
the conclusion that the effects are conserved across at least two different species. 
This novel inhibitory effect of sodium vanadate on the cells of the immune 
system may lead to the development oftherapeutic agents used to control chronic 
inflammatory and autoimmune disorders. In order for this to occur, a molecular target 
must first be uncovered. Potential molecular mechanisms/targets proposed include an 
up-regulation of negative regulators in the TLR signaling pathway, interruption in the 
formation of SNARE complexes, and mimicry of an inhibitor of TACE. 
26 
LITERATURE CITED 
Ade rem, A and Ulevtich, R.J. Toll-like Receptors in the induction of the immune 
response. Nature 406:782-787 (2000). 
Barford, D. Protein phosphatases. Current Opinion in Structural Biology 5(6): 728-734 
{1995). 
Berner, M.D., Sura, M.E., Alves, B.N., and Hunter, K.W. IFN-y primes macrophages for 
enhanced TNF-a expression in response to stimulatory and non-stimulatory amounts of 
microparticulate P-glucan. Immunology Letters 98.1:115-122 (2005). 
Beutler, B. Signal transduction during innate and adaptive immunity. Biochemical 
Society Transactions 29.6: 853-860 (2001). 
Chaineau, M., Danglot L., and Galli, T. Multiple roles ofthe vesicular-SNARE Tl-VAMP in 
post-Golgi and endosomal trafficking. Federation of European Biochemical Societies 
(FEBS) Letters 583.23: 3817-3826 (2009). 
Chen, B.C., Hsieh,S., and Lin, W. Involvement of protein kinases in the potentiation of 
lipopolysaccharide-induced inflammatory mediator formation by thapsigargin in 
peritoneal macrophages. Journal of Leukocyte Biology 69:280-288 (2001). 
Chen, F., Du, Y., Zheng, Z., Chen, G., Zhang, M., Shu, H., Zhai, Z., and Chen, D. Syntenin 
negatively regulates TRAF6-mediated IL-1R/TLR4 signaling. Cellular Signaling 20:666- 
674 (2008). 
Dos Santos, S., Delattre, A.I., De Longueville, F., Bult, H. and Raes, M. Gene expression 
profiling of LPS-stimulated murine macrophages and role of NF-KB and Pl3K/mTOR 
signaling pathways. Annals of the New York Academy of Sciences. 1096:70-77 {2007). 
Essayan, D., Cyclic nucleotide phosphodiesterase (PDE) inhibitors and lmmunodilation. 
Biochemical Pharmacology. 57:965-973 (1999). 
Gordon, S., and Taylor P.R. Monocyte and macrophage heterogeneity. Nature 5:953-964 
(2005). 
Guha, M., and Mackman, N. LPS induction of gene expression in human monocytes. 
Cellular Signaling 13:85-94(2001). 
27 
Gupta, C.P., Sundaram, C., Reuter, S., and Aggarwal B.B. Inhibiting NF-kB activation by 
small molecules as a therapeutic strategy. Biochimica et Biophysica Acta (BBA) - Gene 
Regulatory Mechanisms (2010) DOl:10.1016/j.bbagrm.2010.05.004 
Haslberger, A., Romanin, C., and Koerber, R. Membrane potential modulates release of 
tumor necrosis factor in lipopolysaccharide-stimulated mouse macrophages. Molecular 
Biology of the Ce// 3:451-460 (1992). 
Helming, L., and Gordon, S. The molecular basis of macrophage fusion. lmmunobiology 
785-794(1992). 
Heneberg, P. Use of protein phosphatase inhibitors as promising targeted therapeutic 
drugs. Current Medicinal Chemistry 16: 706-733 (2009). 
Imhof, B.A., and Aurrand-Lions, M. Adhesion mechanisms regulating the migration of 
monocytes." Nature 4: 432-444 (2004). 
Jacobs M.D. and Harrison S.C. Structure of an IKBalpha/NF-KB complex. Ce// 95(6): 749- 
758 (1998). 
Jung, K.J., Lee, E.K., Yu, B.P., and Chung, H.Y. Significance of protein tyrosine 
kinase/protein tyrosine phosphatase balance in the regulation of NF-KB signaling in the 
inflammatory process and aging." Free Radical Biology & Medicine 47:983-991 (2009). 
Kaminska, B. MAPK signaling pathways as molecular targets for anti-inflammatory 
therapy-from molecular mechanisms to therapeutic benefits." Biochimica et 
Biophysica Acta 1754:253-62 (2005). 
Kawai, T. and Akira, S. TLR signaling. Seminars in Immunology 19:24-32 (2007). 
Kitaura, H., Nagata, N., Fujimura, Y., Hotokezaka, H., and Yoshida, N. Effect of IL-12 on 
TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by 
Fas/Fas ligand interaction." The Journal of Immunology 169:4732-4738 (2002). 
Kuby, J. Chapter 3: Innate Immunity. Immunology. 6th ed. New York: W.H. Freeman and 
Company. 52-72 (2007). 
Lacy, P. The role of Rho GTPases and SNAREs in mediator release from granulocytes. 
Pharmacology & Therapeutics 107 :358-76 (2005 ). 
28 
• 
Liu, D.Z., Liang, H., and Chen, C. Switch activation of Pl-PLC downstream signals in 
activated macrophages with Wortmannin. Biochimico et Biophysica Acta 1773. 6:869- 
879 (2007). 
Lu, Y., Yeh, W., and Ohashi, P.S. LPS/TLR4 signal transduction pathway. Cytokine 42: 
145-51 (2008). 
Manderson, A.P. Subcompartments of the macrophage recycling endosome direct the 
differential secretion of IL-6 and TN Fa. The Journal of Cell Biology 178.1: 57-69 (2007). 
Martin, L, Pingle, S.C., Hallam, D.M., Rybak, LP., and Ramkumar, V. Activation ofthe 
adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor 
necrosis factor. The Journal of Pharmacology and Experimental Therapeutics 316.1: 71- 
78 (2006). 
Mcinnes, 1.8., and Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. 
Immunology 7: 429-442 (2007). 
Tanimura, N., Sairoh, S., Matsumoto, F., Akashi-Takamura, S., and Miyake, K. Roles of 
LPS-dependent interaction and relocation of TLR4 and TRAM and TRIF-signaling. 
Biochemical and Biophysical Research Communications 368:94-99 (2008). 
Olszewski, M.B., Groot, A.J., Dastych, J., and Knol, E.F. TNF trafficking to human mast 
cell granules: mature chain-dependent endocytosisl." Journal of Immunology 178 X: 
5701-5709 (2007). 
Sampaio, E.P., Moreira, A.L, Sarno, E.N., Malta, A.M. and Kaplan, G. Prolonged 
treatment with recombinant interferon 3, induces Erythema Nodosum Leprosum in 
lepromatous leprosy patients." Journal of Experimental Medicine 175: 1729-1737 (1992). 
Stow, J.L, Ching, LP., Offenhauser, C., and Sangermani, D. Cytokine secretion in 
macrophages and other cells: pathways and mediators. lmmunobiology 214: 601-612 
(2009). 
Takeda, K., and Akira, S. TLR signaling pathways." Seminars in Immunology 16: 3-9 
(2009). 
Taylor, P. R., Martinez-Pomares, L, Stacey, M., Lin, H. H., Brown, G.D . ,  and Gordon, S. 
Macrophage receptors and immune recognition. Annual Reviews Immunology 23: 901- 
944 (2005). 
29 
Tazi, K.A. Up-regulation ofTNF-alpha production signaling pathways in monocytes from 
patients with advanced cirrhosis: possible role of Akt and IRAK-M." Journal of 
Hepatology 45.2: 280-289 (2006). 
Tran-Thi, T., Decker, K., and Baeuerle, P.A. Differential activation of transcription factors 
NF-kB and AP-1 in Rat Liver Macrophages. Hepatology 22:613-619 (1995). 
Vignery, A. Macrophage fusion: the making of osteoclasts and giant cells. Journal of 
Experimental Medicine 202: 337-341 (2005). 
Wesche, H., Gao, X., Li, X., Kirschning, C.J., Stark, G.R., and Cao, Z. IRAK-M is a novel 
member ofthe Pelle/interleukin-1 receptor-associated kinase (IRAK) family. Journal of 
Biological Chemistry 274:19403-19410 (1999). 
Yanagishita, T., Watanabe, D., Akita, Y., Nakano, A., Ohshima, Y., Tamada, Y., and 
Matsumoto, Y. Construction of novel in vitro epitheloid cell granuloma model from 
mouse macrophage cell line. Archives of Dermatological Research 8:399-403 (2007). 
30 
